Evidence map›Paper›PMID 40390220›Full record

ArticleRecent patents on anti-cancer drug discovery2026

B-9-8, a Novel Harman Dimer, Reverses ABCG2-mediated Chemotherapeutic Drug Resistance.

Rui-Qiang Zhao, Yan Wen, Chao-Yun Cai, Jing-Quan Wang, Pranav Gupta, Zi-Ning Lei, Dong-Hua Yang, Ri-Hui Cao, Zhe-Sheng Chen

Abstract read
PubMed Publisher
In one paragraph

Article in Recent patents on anti-cancer drug discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Rui-Qiang ZhaoDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, USA.
Yan WenDepartment of Pharmacy, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Chao-Yun CaiDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, USA.
Jing-Quan WangDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, USA.
Pranav GuptaDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, USA.
Zi-Ning LeiDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, USA.
Dong-Hua YangDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, USA.
Ri-Hui CaoSchool of Chemistry, Sun Yat-sen University, Guangzhou, China.
Zhe-Sheng ChenDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, USA.

Funding

NIH (National Institutes of Health, Bethesda, MD, United States) 1R15CA143701
6 · The paper itself

Abstract

backgroundMultidrug resistance (MDR) in cancer is a major obstacle to achieving success in clinical chemotherapy. It has been observed that overexpression of ATP-Binding Cassette (ABC) transporters plays a crucial role in MDR.

objectiveThis study aimed to find an effective resistance-reversed agent of ABC transporter. A series of new β-carboline derivatives have been synthesized and are being applied in various invention patents. One of these is B-9-8, a novel harman dimer, which was synthesized to conduct a series of experiments.

methodsIn this study, we investigated whether B-9-8 could reverse ABCG2-mediated drug resistance by using MTT assay, [

resultsThe results showed that B-9-8 could significantly increase the sensitivity to mitoxantrone, SN-38, and topotecan and effectively overcame drug resistance at non-toxic concentrations in ABCG2-overexpressing cells. Further studies showed that B-9-8 increased the intracellular accumulation of [ DISCUSSION: B-9-8, as a novel harman dimer, exhibits its reversal activity against ABCG2- mediated multidrug resistance without obvious cytotoxicity. Its actions of inhibiting ABCG2 efflux function and down-regulating the protein expression of ABCG2 are crucial for overcoming drug resistance. This makes B-9-8 a possible candidate drug for combined chemotherapy. Its inhibitory effect of ATPase activity and the strong affinity to ABCG2 further demonstrate the potential of B-9-8 as a targeted modulator for drug resistance.

conclusionOur findings indicated that B-9-8 could reverse ABCG2-mediated MDR as a potential and reversible modulator in combination with conventional chemotherapeutic drugs.

Indexed as

Antineoplastic AgentsATP Binding Cassette Transporter, Subfamily G, Member 2CarbolinesDrug Resistance, MultipleDrug Resistance, NeoplasmNeoplasm ProteinsCell Line, TumorDimerizationHumansMitoxantroneMolecular Docking SimulationABCG2 protein, humanAntineoplastic AgentsATP Binding Cassette Transporter, Subfamily G, Member 2CarbolinesMitoxantroneNeoplasm Proteins14-b] indol-9-yl) pentane (B-9-8)5-bis (1-methyl-9H-pyrido [3ABC transporter subfamily G member 2 (ABCG2)ATP-binding cassette (ABC) transporterdimerharmanmultidrug resistance (MDR)β-carboline

Identifiers

PMID40390220

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.